APG
PRME icon

Abacus Planning Group’s Prime Medicine PRME Stock Holding History

Abacus Planning Group’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$87.7K Hold
25,188
– – 0.01% 261
2025
Q4 		$87.4K Hold
25,188
– – 0.01% 263
2025
Q3 		$140K Buy
+25,188
New +$102K 0.02% 248

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Abacus Planning Group's PRME Position: Q1 2026 in Review

Abacus Planning Group held its Prime Medicine (PRME) position steady in Q1 2026 at 25,188 shares worth $87.7K. The position accounts for 0.01% of the portfolio, ranked #261.

Abacus Planning Group first reported a position in PRME in Q3 2025 and has held it in 3 quarters since. The position peaked at $140K in Q3 2025. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Abacus Planning Group held 25,188 shares of Prime Medicine worth $87.7K as of Q1 2026.
  • Abacus Planning Group left its Prime Medicine share count unchanged in Q1 2026.
  • Prime Medicine made up 0.01% of Abacus Planning Group's portfolio in Q1 2026, its #261 holding.
  • Abacus Planning Group first reported a position in Prime Medicine in Q3 2025 and has held it in 3 quarters since.
  • Abacus Planning Group's Prime Medicine position peaked at $140K in Q3 2025.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Abacus Planning Group's 13F filing for Q1 2026, filed 8 Apr 2026.